
BMS extends its cost-cutting drive by another $2bn
BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.

Clinical trends for 2025: A year of change
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.

Pressure relieved on AZ as details of Chinese probe emerge
AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.

Newel's VR therapy for chronic pain nears EU market
Newel Health has been granted EU certification for its VR-based digital therapeutic for chronic pain, clearing the way for its launch in Europe.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content

7th Neuroimmunology Drug Development Summit
7th Neuroimmunology Drug Development Summit | February 25-27 2025 | Boston, MA

3rd Precision Medicine in Inflammatory Bowel Disease Summit ...
Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push

15th World Clinical Biomarkers & Companion Diagnostics Summi...
As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the clinic, the 15th World Clinical Biomarkers & Companion Diagno

AI Literacy for Pharma Marketing Career Success
Preparing for AI Success in 2025 and Beyond: Insights from Our 2024 Research.

Datapharm partners with phactMI to enhance medicines informa...
Datapharm, a leading medicines information solution provider in Europe, is delighted to announce its expansion into the United States (US) through a new partnership with the Pharma Collabor